Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Emergent BioSolutions Inc.NYSE: EBS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA dips below year-ago levels
Q1 FY2026 EBITDA of $48.5M fell 63.6% year over year, behind the +28.1% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at +148.3% a year.
Context
- EBITDA amounted to 32.4% of revenue in FY2025, up 27.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $175.67M (-26.9%) for the fiscal year ending Dec 2026, a slowdown from the +350.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $48.5M+488.0% QoQ
- Last fiscal yearDec 2025
- $240.4M+350.2% YoY
- LTMMar 2026
- $154.5M+28.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -63.6% | +35.3% | +99.0 pp |
| 1 year | +350.2% | -26.9% | -377.1 pp |
| 3-year CAGR | +148.3% | +0.7% | -147.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 240.4M USD
- Year-over-year change
- +350.2%
- 4-year CAGR
- -16.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 240.4M | +350.2% |
| FY2024 | 2024-12-31 | 53.4M | +213.6% |
| FY2023 | 2023-12-31 | (47M) | -399.4% |
| FY2022 | 2022-12-31 | 15.7M | -96.9% |
| FY2021 | 2021-12-31 | 504.2M | — |
EBITDA vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.1% is the 6th highest of 11, against a peer median of +16.3%.
- EBITDA amounts to 22.8% of revenue for EBS, versus a peer median of 29.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $154.5M USD | +28.1% | +148.3% | 22.8% | |
| LTM Mar 2026 | $131.28M USD | +170.9% | — | 43.8% | |
| LTM Mar 2026 | CA$49.42M CAD | +201.3% | — | 5.3% | |
| LTM Mar 2026 | $39.9M USD | +145.1% | — | 9.5% | |
| LTM Mar 2026 | $37.31M USD | +1061.2% | +22.4% | 7.3% | |
| LTM Mar 2026 | $27.5M USD | -56.2% | -11.5% | 29.3% | |
| LTM Mar 2026 | -$42.27M USD | -2.3% | — | — | |
| LTM Mar 2026 | -$51.63M USD | -40.6% | — | 102.7% | |
| LTM Mar 2026 | -$74.72M USD | +35.0% | — | 129.0% | |
| LTM Mar 2026 | -$176.6M USD | -34.4% | — | — | |
| LTM Mar 2026 | -$184.67M USD | -43.8% | — | — | |
| Peer median (excluding EBS) | — | +16.3% | +5.4% | 29.3% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1.12B | 1.05B | 1.04B | 742.9M |
| Cost of Revenue | 980.4M | 644.5M | 689.3M | 668.2M | 392.3M |
| Gross Profit | 793.2M | 473M | 360M | 375.4M | 350.6M |
| Gross Margin | 44.7% | 42.3% | 34.3% | 36.0% | 47.2% |
| Research & Development | 235.2M | 188.3M | 111.4M | 70.7M | 53.8M |
| Selling, General & Admin | 348.7M | 339.5M | 356.7M | 298.7M | 186.6M |
| Operating Expenses | 451.8M | 643M | 1.09B | 484.1M | 240.4M |
| Depreciation & Amortization | 118.2M | 125M | 121.1M | 105.6M | 98.3M |
| EBITDA | 504.2M | 15.7M | (47M) | 53.4M | 240.4M |
| EBITDA Margin | 28.4% | 1.4% | -4.5% | 5.1% | 32.4% |
| Operating Income | 341.4M | (170M) | (726.4M) | (108.7M) | 110.2M |
| Operating Margin | 19.2% | -15.2% | -69.2% | -10.4% | 14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 34.5M | 37.3M | 87.9M | 71M | 59.3M |
| Other Income / Expenses | (38.2M) | (49M) | (4.8M) | (34.2M) | (27.4M) |
| Income Before Tax | 303.2M | (219M) | (731.2M) | (142.9M) | 82.8M |
| Pre-Tax Margin | 17.1% | -19.6% | -69.7% | -13.7% | 11.1% |
| Income Tax Expense | 83.7M | (7.4M) | 29.3M | 47.7M | 30.2M |
| Net Income | 219.5M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Net Margin | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| EPS (Basic) | 4.10 | (4.22) | (14.85) | (3.60) | 0.98 |
| EPS (Diluted) | 4.06 | (4.22) | (14.85) | (3.60) | 0.93 |
| Weighted Avg Shares | 53.5M | 50.1M | 51.2M | 53M | 53.5M |
| Weighted Avg Shares (Diluted) | 54.1M | 50.1M | 51.2M | 53M | 56.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.